E-DRUG: Independent Drug & Healthcare Newsletter for April 2016
-----------------------------------------------------------------------------------
Newsletter, April 2016
If your friends or colleagues would be interested, forward this email and invite them to sign up for the free Newsletter.
View the table of contents for the current issue
Subscribe to Prescrire International
In Prescrire's Spotlight this month
Towards better patient care: drugs to avoid in 2016
FEATURED REVIEW Announced in conjunction with the annual Prescrire Awards and published in the April issue of Prescrire International, the 2016 update of Prescrire's list of drugs to avoid includes 74 drugs that are more harmful than beneficial in all of the indications for which they are authorised in France. Notable changes this year include the addition of the widely prescribed drugs citalopram, escitalopram and diclofenac amongst the drugs to avoid. Full review (7 pages) available for free download.
Read more
In the April issue of Prescrire International: adverse effects of SSRIs, gliptins and mirabegron
FREE DOWNLOAD In this sample page from the Adverse Effects section of the April issue: extrapyramidal reactions with certain antidepressants, joint pain with gliptins and the cardiovascular effects of incontinence drug mirabegron. Full text available for free download.
Read more
Venlafaxine: unjustifiable cardiovascular risks
There is considerable evidence that venlafaxine carries an increased risk of adverse cardiovascular effects and of overdose deaths, compared with most other "selective" serotonin reuptake inhibitors (SSRIs), whereas the efficacy of all SSRIs is similar - and limited.
Read more
Allergic rhinitis during pregnancy: opt for the lowest risk
When drug treatment for allergic rhinitis is recommended in a pregnant woman, there are various options that expose the patient to few risks: sodium cromoglicate or azelastine nasal inhaler or an oral or nasal non-sedating and non-antimuscarinic antihistamine.
Read more
International nonproprietary names: more informative
The goal of a drug's International nonproprietary name (INN) is to provide information about the drug's mechanism of action or pharmacotherapeutic group. A far cry from brand names, which are designed to facilitate sales.
Read more
Independent Drug & Healthcare Newsletter for April 2016